Do you struggle with chronic low back pain from Ankylosing Spondylitis?

Research studies are enrolling now!

Those who qualify may receive*:

  • Payment up to $500, which varies by study
  • Study-related care at no cost from local doctors
  • Study medication at no cost

Ready to get started? Click Here.

Ankylosing Spondylitis (ank-kih-low-sing spon-dill-eye-tiss), or AS, is a form of arthritis that attacks the spine. Many people who have this condition feel ongoing back pain, back stiffness in the morning, or buttock pain that alternates between the left and right sides. Some people feel more severe symptoms than others, or they may feel pain in different areas of the body. Ankylosing Spondylitis, also known as axial spondyloarthritis or axSpA, is a lifelong condition that could lead to disability.

You may not have found pain relief with your current medications. Better treatment options are needed for people who suffer with chronic pain from AS. Right now, doctors are looking for people like you to take part in local AS research studies. See if you qualify today – space is limited. No health insurance or referrals are needed to enroll.

Take the next step to see if you qualify for local research studies for people with Ankylosing Spondylitis. But don’t delay — space is limited!

* In a research study, the participants may receive investigational study product or may receive an inactive substance, or placebo, depending on the study design. Participants receive study-related care from a doctor/research team for the duration of the study. Reasonable payments will be made for participation and the length of the study may vary.

Ready to get started?

Click here.

or

Call 844-990-9922

How does it work?

1

Tell us a little bit about yourself

2

Answer some questions about your health

3

We will connect you to available studies in your area

Just takes a few minutes

AcurianHealth

AcurianHealth helps connect people with research studies that offer treatment under development. Since 1998, AcurianHealth has referred 1 million study candidates to 800 studies in 70 countries.